Transcatheter Edge-to-Edge Repair in Valvular Heart Disease: A Comprehensive Exploration of Equipment, Efficacy, Gender, Racial, and Socioeconomic Disparities, and Future Prospects
- 6 July 2024
- journal article
- review article
- Published by Wolters Kluwer Health in Cardiology in Review
Abstract
The 2 primary components of valvular heart disease are mitral regurgitation (MR) and tricuspid regurgitation (TR). Transcatheter edge-to-edge repair (TEER) is an advanced, minimally invasive procedure that has recently displayed encouraging outcomes in the treatment of these pathologies. TEER offers a nonsurgical alternative for individuals diagnosed with conditions deemed to be high-risk surgical candidates. Currently, the TEER procedure employs devices such as MitraCLIP and TriCLIP, as well as innovative PASCAL (transcatheter valve repair system used for mitral and tricuspid valve repair) and FORMA (repair system used for tricuspid valve repair) repair systems. In the COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation) trial enrolling 614 patients to test the efficacy of TEER in MR, a significant reduction in hospitalization due to heart failure was observed at 24 months in the MitraClip + guideline-directed medical therapy (GDMT) group (35.8%) than in the GDMT-alone group (67.9%), HR, 0.53; P < 0.001, lower rate of all-cause mortality at 29.1% compared with 46.1% (P < 0.001), lower risk of cerebrovascular events (P = 0.001), and lower mortality due to cardiovascular events (P < 0.001). In another trial, patients with moderate TR or greater than New York Heart Association Class II or higher underwent TEER using the TriClip for the management of TR. The outcomes were encouraging, with 86% of patients showing a reduction in TR severity of at least one grade. As the technology and research surrounding TEER continue to progress, a more extensive range of patients are expected to qualify for TEER procedures. Our comprehensive review sought to extensively explore the background, equipment used, effectiveness of MR and TR, potential side effects, future prospects, and ongoing trials associated with TEER. We further discuss the existing gender, racial, and socioeconomic disparities in the realm of TEER.-Keywords
This publication has 67 references indexed in Scilit:
- Transcatheter edge‐to‐edge repair for mitral regurgitation using PASCAL or MitraClipCatheterization and Cardiovascular Interventions, 2023
- Edge-to-Edge Percutaneous Mitral Repair for Functional Ischaemic and Non-Ischaemic Mitral Regurgitation: A Systematic Review and Meta-AnalysisESC Heart Failure, 2022
- Sex differences in outcomes of transcatheter edge‐to‐edge repair with MitraClip: A meta‐analysisCatheterization and Cardiovascular Interventions, 2022
- Complications Following MitraClip ImplantationCurrent Cardiology Reports, 2021
- Impact of gender on in‐hospital mortality and 90‐day readmissions in patients undergoing transcatheter edge‐to‐edge mitral valve repair: Analysis from the National Readmission DatabaseCatheterization and Cardiovascular Interventions, 2021
- Subacute hemolytic anemia after transcatheter edge‐to‐edge mitral valve repair: A case reportCatheterization and Cardiovascular Interventions, 2019
- Infective endocarditis following transcatheter edge‐to‐edge mitral valve repair: A systematic reviewCatheterization and Cardiovascular Interventions, 2018
- The MitraClip Asia‐Pacific registry: Differences in outcomes between functional and degenerative mitral regurgitationCatheterization and Cardiovascular Interventions, 2015
- Using Imaging to Guide Patient Selection and Performance of Catheter-Based Mitral Valve Repair for Mitral RegurgitationJournal of Cardiovascular Translational Research, 2013
- Maximizing the benefit of minimally invasive surgeryJournal of Surgical Oncology, 2013